CAJ | 학술논문

目的：探讨TACE联合立体定向放疗治疗肝癌伴门静脉癌栓的患者生存率及不良反应。方法选取84例肝癌伴门静脉癌栓患者作为研究对象。随机分为治疗组和对照组，各42例。治疗组采用TACE联合立体定向放疗，对照组仅采用TACE治疗。结果治疗组和对照组经治疗后12个月和18个月的生存率分别为83．34％、42．92％和57．14％、23．83％，差异具有统计学意义（P＜0．05和P＜0．01），而2组治疗后6个月的生存率及不良反应发生率无明显差异。结论 TACE联合立体定向放疗延长了肝癌伴门静脉癌栓患者的生存期，提高了患者的生活质量，改善了预后。
목적：탐토TACE연합입체정향방료치료간암반문정맥암전적환자생존솔급불량반응。방법선취84례간암반문정맥암전환자작위연구대상。수궤분위치료조화대조조，각42례。치료조채용TACE연합입체정향방료，대조조부채용TACE치료。결과치료조화대조조경치료후12개월화18개월적생존솔분별위83．34％、42．92％화57．14％、23．83％，차이구유통계학의의（P＜0．05화P＜0．01），이2조치료후6개월적생존솔급불량반응발생솔무명현차이。결론 TACE연합입체정향방료연장료간암반문정맥암전환자적생존기，제고료환자적생활질량，개선료예후。
Objective To investigate the survival rate and adverse reactions of TACE and stereotactic radiotherapy for hepatocellular carcinoma with portal vein thrombosis .Methods 84 cases of hepatocellular carcinoma with portal vein thrombosis patients were selected as research subjects .The patients were randomly divided into the treatment group and the control group , each group contain 42 cases.The treatment group were treated with TACE and stereotactic radiotherapy;and the control group re-ceived only TACE treatment .Results Survival rates of the treatment group and the control group 12 months and 18 months after treatment were 83.34%,42.92% and 57.14%,23.83%,and the difference was significant (P<0.05 and P<0.01),while survival rates and the incidence of adverse reactions of the 2 groups 6 months after treatment had no significant difference .Con-clusion TACE combined with stereotactic radiotherapy for hepatocellular carcinoma with portal vein thrombosis prolongs surviv -al,improves quality of life and prognosis of the patients .